After receiving TNF treatment for 12 months, more than half of patients with axSpA and IBD experienced clinical remission.

Published Date: 11 May 2023

52 percent of axSpA cohort patients and 76 percent of IBD cohort patients had achieved clinical remission after a year.

Read Full News

Latest News

Pediatric Cancer in the 2000s: Uneven Survival Gains Seen

A large database study found overall 5- and 10-year improvement in pediatric cancer survival, but some cancers lag others, and demographic factors seem to influence trends.

A Better Test for Finding Residual Pancreatic Cancer?

A KRAS-directed ctDNA assay solidly outperformed standard next-generation sequencing in detecting residual pancreatic cancer. Could it eventually help guide KRAS-targeted therapies?

Medical Journal Retracts Paper on Amgen’s Tavneos Drug Trial After FDA Findings

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported ⁠approval of Amgen’s rare-disease drug, citing concerns that...

Abivax Inflammatory Bowel Drug Shows Benefit in Relapsed and Non-responding Patients

Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients ⁠achieve remission, sending U.S.-listed shares of the Paris-based...

US, Mexico Inaugurate Sterile Fly Plant in Chiapas in Cross-border Screwworm Fight

METAPA, Mexico June 27 - Senior Mexican and U.S. officials inaugurated a sterile fly production plant in southern Chiapas on Saturday, a milestone in efforts to contain...

Which Drug Is Better for Remission in Ulcerative Colitis?

In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and steroid-free clinical remission than ustekinumab and vedolizumab.

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Todays Updates

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Enhancing Comprehensive Biomarker Testing and Biomarker-Directed Treatment Selection

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Advancing Care in ES-SCLC: Personalized Strategies, New Therapies, and Real-World Insights

Adjuvant Combination for Kidney Cancer Gets FDA's Blessing

Belzutifan and pembrolizumab together reduced the risk of disease recurrence or death

FDA Approves Prostate Cancer Combo That Warranted Advisory Meeting

Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors

Talquetamab Regimens Boost Survival in Multiple Myeloma

"Combinations represent additional options for early-line treatment," researcher says

In High-Risk B-Cell ALL, Swapping Out Chemo for Blinatumomab Improves Outcomes

The bispecific T-cell engager also reduced toxicity in newly diagnosed kids

Timely 'Nudges' Can Help Encourage More End-of-Life Conversations in Cancer

A combination of clinician and patient prompts worked best, but talks remained infrequent

Latest News

A large database study found overall 5- and 10-year improvement in pediatric cancer survival, but some cancers lag others, and demographic factors seem to influence trends.

A KRAS-directed ctDNA assay solidly outperformed standard next-generation sequencing in detecting residual pancreatic cancer. Could it eventually help guide KRAS-targeted therapies?

The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported ⁠approval of Amgen’s rare-disease drug, citing concerns that...

Abivax said on Monday its experimental ulcerative colitis drug helped harder-to-treat groups of patients ⁠achieve remission, sending U.S.-listed shares of the Paris-based...

METAPA, Mexico June 27 - Senior Mexican and U.S. officials inaugurated a sterile fly production plant in southern Chiapas on Saturday, a milestone in efforts to contain...

In patients with ulcerative colitis exposed to anti-TNF therapy, tofacitinib is linked to higher rates of clinical and steroid-free clinical remission than ustekinumab and vedolizumab.

News All Time

Genotype-Guided Dosing Reduces Irinotecan Toxicity

Using UGT1A1 genotype to guide irinotecan dosing curbs severe side effects in patients with impaired metabolism of the drug.

Noninvasive Magnetic Therapy Effective in Fecal Incontinence

A novel noninvasive magnetic therapy is effective, safe, and well tolerated in patients with fecal incontinence, reducing symptom burden and disease severity.

Spyre Says Bowel Disease Drug Cuts Inflammation in Mid-stage Trial

Spyre Therapeutics said on Monday its experimental bowel disease drug met the main goal ⁠of significantly reducing disease severity in a mid-stage trial.

EMA Tightens Liver Safety Checks for Rare Vasculitis Drug

The EMA has reinforced enhanced liver surveillance for a vasculitis therapy after cases of severe and sometimes fatal drug-induced liver injury and vanishing bile duct syndrome.

Indian Cancer Patients Battle Shortage Of Key Drugs as Platinum Costs Surge

Kumar Ajit spent more than a week calling dozens of pharmacies in India before he tracked down the platinum-based cancer drug cisplatin his 70-year old mother needed to...

Simple Test May Cut Colonoscopy Frequency After Polypectomy

Testing fecal hemoglobin levels may help optimize colonoscopy resource allocation without compromising CRC risk reduction.

Immunotherapy Plus TACE Improves PFS in Unresectable HCC

The study adds to growing evidence that immunotherapy and chemoembolization prolong progression-free survival.

Flesh-eating Screwworm Confirmed in Texas Calf as Parasite Crosses Border From Mexico

New World screwworm, a parasitic fly that eats warm-blooded animals alive, has been found in a calf in Texas, the U.S. Department of Agriculture said on Wednesday evening,...

Iza-Bren Beats Chemo in Second-Line Esophageal Cancer

In a phase 3 trial, izalontamab brengitecan shows superiority to chemotherapy in previously treated esophageal squamous cell carcinoma, but questions remain about generalizability outside China.

Antibiotic Effects on the Gut Detected Up to 8 Years Later

Changes in gut microbiome diversity are observed with certain antibiotic drugs years later, even after just one course of therapy.

Natural Supplements Linked to Cases of Severe Liver Injury

Experts warn that concentrated herbal and dietary supplements are increasingly linked to severe liver injury, while regulation remains limited.

Remote Monitoring in Cirrhosis Could Reduce Admissions

A digital monitoring system for advanced cirrhosis may help detect deterioration earlier and reduce hospital admissions.

Blood Test Added to US Colorectal Cancer Screening Options

People who skip colorectal cancer screening because colonoscopy or stool testing seems too burdensome now have a blood test option from Guardant Health among recommendations...

Can Intraperitoneal Paclitaxel Improve OS in Gastric Cancer?

A phase 3 trial explores whether adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improves overall survival in patients with gastric cancer and peritoneal metastasis.

Pancreatic Cancer Testing Falls Short of Goals

Researchers conducted a cross-sectional electronic survey to see whether respondents were offered and completed germline genetic testing following a pancreatic ductal adenocarcinoma diagnosis.

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

Recommended News For You

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

Smart exercise planning could boost recovery for people with cancer

Alternative Medicine for Breast Cancer: Study Raises Concern

Three-Drug Regimens Make Case for a Role in Untreated and Relapsed/Refractory CLL

Report: High risk of lung cancer from respirable crystalline silica even below the current occupational exposure limit

Patients with head and neck cancer who cannot receive cisplatin now have new hope.

Recommended Articles For You

Clinical Methods in Hematology and Quality Improvement 

Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection 

Gene Therapy for Hemophilia: A New Hope on the Horizon 

Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Inner Thoughts of Leonard Bernstein, the "Maestro".

2.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

3.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

4.

Parents, teachers at Missouri school want answers after string of cancer diagnoses

5.

A promising medication could slow brain tumors in children.

1.

Future-Ready Cancer Screening: What Every Clinician Should Know in 2025

2.

Cancer Evolution and Therapeutic Resistance: Mechanisms, Clinical Insights, and Emerging Strategies

3.

Targeting Cancer Stem Cells in Solid Tumors: Mechanisms, Clinical Implications, and Therapeutic Advances

4.

Partial Gland Ablation in Prostate Cancer: Oncologic Outcomes in Intermediate-Risk Cases

5.

Generative AI for Adaptive Oncology Trial Design

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

2.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

3.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC

4.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

5.

Current Scenario of Cancer- The Incidence of Cancer in Men

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot